Arijita Deb, United States of America

Merck & Co., Inc. Merck & Co., Inc.

Poster Author Of 5 e-Posters

Online Abstracts Population Sciences - Epidemiology, Economics, and Mathematical Modelling D1 Epidemiology, Economics, and Mathematical Modelling
Online Abstracts Vaccines - Impact of Vaccine programs and Serotype Replacement C2 Impact of Vaccine programs and Serotype Replacement
Online Abstracts Population Sciences - Epidemiology, Economics, and Mathematical Modelling D1 Epidemiology, Economics, and Mathematical Modelling
Online Abstracts Vaccines - Pneumococcal Vaccines Development C1 Pneumococcal Vaccines Development
Online Abstracts Vaccines - Pneumococcal Vaccines Development C1 Pneumococcal Vaccines Development

Author Of 5 Presentations

ECONOMIC BURDEN OF PNEUMOCOCCAL DISEASE IN INDIVIDUALS AGED 15 YEARS AND OLDER IN SPAIN: AN APPROXIMATION BASED ON THE CONJUNTO MÍNIMO DE DATOS-HOSPITALIZACIÓN (CMBD-H) (ID 780)

Abstract

Background

Streptococcus pneumoniae is a major cause of morbidity and mortality worldwide, being the most common etiological pathogen of pneumonia, meningitis and bacteremia. This study assessed the healthcare resource utilization and costs associated with inpatient admissions for pneumonia and invasive pneumococcal disease (IPD) in individuals aged 15 years and older in Spain during 2015.

Methods

A retrospective, descriptive study was conducted using Conjunto Mínimo de Datos-Hospitalización (CMBD-H), a publicly available database provided by the Spanish Ministry of Health capturing approximately 90% of hospitalization episodes.

The economic burden of pneumococcal disease was calculated by multiplying the average cost associated with an inpatient admission for pneumonia or IPD by the number of each type of episode. Additionally, the length of stay (days of hospitalization) due to pneumococcal disease was estimated

Results

The aggregated annual economic burden of pneumococcal disease was 54.1 million euros ($60.1 million) These represented over 97,390 hospitalization days, 80% of which were associated with pneumococcal pneumonia. Pneumococcal meningitis has the highest average cost per episode, 10,706 euros ($11,904) followed by the average cost of a septicemia episode, 9,338 euros ($10,382).

Conclusions

These results demonstrate the substantial economic impact of pneumococcal disease on the Spanish National Health System.

Hide

HEALTH AND ECONOMIC IMPACT OF 15-VALENT PNEUMOCOCCAL CONJUGATE VACCINE (PCV15) SEROTYPES IN ADULTS 65 YEARS AND OLDER IN CANADA (ID 737)

Abstract

Background

The objective of this study is to quantify the epidemiologic and economic burden of pneumococcal disease attributable to 15-valent pneumococcal conjugate vaccine (PCV15) serotypes in Canada.

Methods

A published Markov model was adapted to estimate the burden of PCV15 serotypes in a cohort of unvaccinated Canadian adults aged 65 and older who were tracked from 2015 until death. The Markov model included the following health states: no pneumococcal disease, invasive pneumococcal diseases (IPD), non-bacteremic pneumococcal pneumonia (NBPP) and death. Economic burden was estimated from a publicly funded health care payer perspective, by multiplying the number of inpatient/outpatient visits by the cost per inpatient/outpatient visits.

Results

The model resulted in an estimated 7,834 cases of IPD and 110,372 cases of NBPP hospitalizations. Of these, there were 1,684 cases of IPD related deaths and 8,444 cases of NBPP related death. Total lifetime discounted healthcare costs attributable to PCV15 serotypes were estimated to be approximately $874.6 million. 38.5% of these costs ($337.1 million) were attributable to serotypes 22F and 33F and 22.2% were attributable to serotype 3.

Conclusions

The serotypes included in PCV15 contribute considerably to the health and economic burden of pneumococcal disease among older adults in Canada.

Hide

HEALTH AND ECONOMIC IMPACT OF 15-VALENT PNEUMOCOCCAL CONJUGATE VACCINE (PCV15) SEROTYPES IN ADULTS 65 YEARS AND OLDER IN THE U.S. (ID 744)

Abstract

Background

This analysis quantifies the epidemiologic and economic burden of pneumococcal disease attributable to 15-valent pneumococcal conjugate vaccine (PCV15) serotypes in a hypothetical cohort of US adults aged 65 years and older in the US.

Methods

A Markov model was used to estimate pneumococcal disease cases, deaths and costs attributable to PCV15 serotypes. A cohort of unvaccinated adults aged ≥65 years from 2017 were tracked until death. Economic burden was estimated from a payer perspective, by multiplying the number of inpatient/outpatient visits by the cost per inpatient/outpatient visits. Costs were discounted at 3% per year.

Results

An estimated 74,956 cases of IPD; 10,336 cases of IPD related deaths; 2,286,581 cases of NBPP hospitalizations and 135,566 cases of NBPP related deaths were attributable to PCV15 serotypes in adults aged ≥65 years in the U.S. Total lifetime discounted healthcare costs attributable to PCV15 serotypes were estimated to be approximately $19.9 million. 36.3% of these cases, deaths and costs were attributable to serotypes 22F and 33F and 42.4% were attributable to serotype 3.

Conclusions

PCV15 serotypes contribute to substantial health and economic burden of pneumococcal disease among older adults (aged ≥65 years) in the U.S., majority of which is attributable to the serotypes 3, 22F, and 33F.

Hide

CLINICAL AND ECONOMIC BURDEN OF PNEUMOCOCCAL DISEASE AMONG INDIVIDUALS AGED 16 YEARS AND OLDER IN GERMANY (ID 748)

Abstract

Background

The study assessed the incidence rate of all-cause pneumonia (ACP) and invasive pneumococcal disease (IPD) and associated direct medical costs among individuals aged 16 years and older in Germany.

Methods

ACP and IPD were identified using ICD-10-GM codes in the InGef database from 2014 to 2017. Incidence rate was expressed as the number of episodes per 100,000 person-years. Direct medical costs were estimated as the total cost of all inpatient and outpatient visits, divided by the total number of episodes.

Results

The annual incidence of IPD per 100,000 person-years were as follows: 16 to 49 years: 7.2; 50 to 59 years: 29.4; 60 to 69 years: 69.1; and >=70 years: 207.1. The annual incidence of ACP per 100,000 person-years were as follows: 16 to 49 years: 438.8; 50 to 59 years: 809.6; 60 to 69 years: 1199.5; and >=70 years: 2770.9. The mean direct medical costs for IPD and ACP per episode were estimated to be €4551 and €993 respectively. The aggregate direct medical costs for IPD and ACP were estimated to be €28.5 million and €117.7 million respectively.

Conclusions

The clinical and economic burden of IPD and ACP among German adults is substantial regardless of age.

Hide

BURDEN OF DISEASE ASSOCIATED WITH PNEUMONIA AND INVASIVE PNEUMOCOCCAL DISEASE (IPD) IN INDIVIDUALS AGED 15 YEARS AND ABOVE IN SPAIN (ID 774)

Abstract

Background

The available burden of disease (BoD) studies in pneumococcal disease in Spain are limited to analyzing data restricted to specific geographical regions. This study assessed the clinical burden associated with streptococcus pneumoniae in Spain.

Methods

A retrospective study was conducted using Conjunto Mínimo de Datos-Hospitalización (CMBD-H), a publicly available database provided by the Spanish Ministry of Health covering approximately 90% of hospitalization episodes.

The study population consisted of individuals aged 15 years and older who were hospitalized with a diagnosis of pneumonia, bacteremia and meningitis due to Streptococcus Pneumoniae in 2015.

Results

In 2015, the estimated burden of pneumococcal disease potentially avoidable through vaccination represented 10,274 inpatient admissions including 9,015 cases of pneumonia, 309 cases of meningitis and 950 cases of septicemia. Additionally, 867 deaths were registered during these hospitalization episodes. The information available in CMBD-H only captures individual hospitalization episodes and cannot capture per patient hospitalization, therefore it could be used as an approximation to estimate disease incidence, but not real incidence, which is a limitation of the study.

Conclusions

Pneumococcal disease still contributes to substantial morbidity and mortality among individuals aged 15 years and older in Spain.

Hide